The United States legal cannabis industry, now valued at approximately $30 billion, may benefit significantly from recent federal policy shifts aimed at easing tax burdens and regulatory hurdles. The Trump administration has initiated measures to reclassify cannabis, reducing its federal restrictions and potentially providing substantial financial relief to cannabis companies.

Last month, federal authorities moved to relax controls on medical marijuana by reclassifying it from a Schedule I substance—grouped with drugs like heroin—to a lower-risk category akin to prescription medications such as Tylenol. While this adjustment stops short of legalizing medical marijuana under federal law, it facilitates a process overseen by the Drug Enforcement Administration (DEA) that could lead to broader reclassification of cannabis products.

Currently, many cannabis businesses face effective tax rates nearing 70 percent because they are taxed based on income rather than profits, a rate more than double that of most other sectors. Under the proposed new classification, companies licensed to sell medical marijuana would gain the ability to claim standard tax deductions for expenses such as rent and payroll, potentially cutting tax bills nearly in half. A wider reclassification encompassing recreational marijuana could extend similar tax benefits to that segment as well.

The Treasury Department is reportedly considering retroactively applying these tax breaks, a move that could alleviate the approximately $2.24 billion in federal taxes owed by legal cannabis firms in 2025, according to Whitney Economics. Several major publicly traded companies, including Florida-based Trulieve and New York’s Curaleaf, account for over $1.6 billion of this tax liability, based on their disclosures.

Despite these developments, details on the implementation and scope of the changes remain unclear. Both the Treasury and Internal Revenue Service have yet to release formal guidance, though the DEA has begun allowing cannabis businesses to register, signaling momentum toward regulatory updates. Uncertainty persists regarding how businesses involved in both medical and recreational cannabis sales will be treated under the new framework.

Industry analysts note that many cannabis operators are contending with rising supply chain costs and oversupply, leading to price declines in 24 of the 40 states where marijuana is legal for medical or recreational use. Tax relief could help improve profitability for numerous companies. Austin Ownbey, a partner at Akerman LLP in Washington, D.C., stated that such breaks “would make some businesses profitable or more profitable.”

Legal advisors advise caution, as many cannabis companies have delayed filing tax returns pending reclassification outcomes. Jeffrey Schultz, a cannabis attorney with Foley Hoag LLP, reported advising clients granted IRS filing extensions to consider postponing submission further, while those who have already filed may need to amend returns.

Executives from Trulieve, Curaleaf, and Tilray—companies with cannabis operations spanning the U.S. and Canada—have expressed interest in investing more in research to secure approval for cannabis-based treatments targeting cancer, nerve pain, and seizures. Kim Rivers, CEO of Trulieve and a key figure in persuading President Trump to issue an executive order last December directing the Department of Justice to expedite cannabis reclassification, emphasized the transformation of the industry.

“This is not some plants in a closet or on a dirt floor,” Rivers remarked. “This is real, regulated, highly nuanced business. Millions of Americans are finding relief and want to have assurance that these products are backed by real research in the United States.”